The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth

被引:38
|
作者
Montgomery, Elizabeth T. [1 ]
Atujuna, Millicent [2 ]
Krogstad, Emily [1 ]
Hartmann, Miriam [1 ]
Ndwayana, Sheily [2 ]
O'Rourke, Shannon [1 ]
Bekker, Linda-Gail [2 ]
van der Straten, Ariane [1 ,3 ]
Minnis, Alexandra M. [1 ,4 ]
机构
[1] RTI Int, Ctr Global Hlth SSES, Womens Global Hlth Imperat, San Francisco Project Off, San Francisco, CA USA
[2] Desmond Tutu HIV Res Ctr, Cape Town, South Africa
[3] Univ Calif San Francisco, Ctr AIDS Prevent Studies, Dept Med, San Francisco, CA 94143 USA
[4] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
关键词
South Africa; youth; PrEP; sustained-release long-acting PrEP; implants; injections; DAPIVIRINE VAGINAL RING; PREVENTION; ACCEPTABILITY; TRIAL;
D O I
10.1097/QAI.0000000000001960
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Long-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches. Methods: Ninety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience. Results: Irrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods. Conclusions: Narrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact.
引用
收藏
页码:542 / 550
页数:9
相关论文
共 50 条
  • [21] Pre-exposure prophylaxis as an opportunity for engagement in HIV prevention among South African adolescents
    LoVette, Ashleigh
    Kuo, Caroline
    Giovenco, Danielle
    Hoare, Jacqueline
    Underhill, Kristen
    Operario, Don
    SAHARA J-JOURNAL OF SOCIAL ASPECTS OF HIV-AIDS, 2022, 19 (01) : 1 - 7
  • [22] Assessing Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among Young Adult Sexual Minority Men and Transgender Women
    Weeden, Terrance
    Garofalo, Robert
    Johnson, Amy K.
    Schnall, Rebecca
    Scherr, Thomas
    Kuhns, Lisa M.
    Cervantes, Marbella
    ACADEMIC PEDIATRICS, 2024, 24 (07) : 1110 - 1115
  • [23] Long acting systemic HIV pre-exposure prophylaxis: an examination of the field
    William R. Lykins
    Ellen Luecke
    Daniel Johengen
    Ariane van der Straten
    Tejal A. Desai
    Drug Delivery and Translational Research, 2017, 7 : 805 - 816
  • [24] Long acting systemic HIV pre-exposure prophylaxis: an examination of the field
    Lykins, William R.
    Luecke, Ellen
    Johengen, Daniel
    van der Straten, Ariane
    Desai, Tejal A.
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2017, 7 (06) : 805 - 816
  • [25] Long-Acting Injection and Implant Preferences and Trade-Offs for HIV Prevention Among South African Male Youth
    Montgomery, Elizabeth T.
    Browne, Erica N.
    Atujuna, Millicent
    Boeri, Marco
    Mansfield, Carol
    Sindelo, Siyaxolisa
    Hartmann, Miriam
    Ndwayana, Sheily
    Bekker, Linda-Gail
    Minnis, Alexandra M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 87 (03) : 928 - 936
  • [26] Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa
    Chih-Yuan Cheng
    Matthew Quaife
    Robyn Eakle
    Maria A. Cabrera Escobar
    Peter Vickerman
    Fern Terris-Prestholt
    BMC Public Health, 19
  • [27] Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa
    Cheng, Chih-Yuan
    Quaife, Matthew
    Eakle, Robyn
    Escobar, Maria A. Cabrera
    Vickerman, Peter
    Terris-Prestholt, Fern
    BMC PUBLIC HEALTH, 2019, 19 (1) : 996
  • [28] Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the US
    Parsons, Jeffrey T.
    Rendina, H. Jonathon
    Whitfield, Thomas H. F.
    Grov, Christian
    AIDS AND BEHAVIOR, 2016, 20 (07) : 1390 - 1399
  • [29] Multitasking Pharmacophores Support Cabotegravir-Based Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)
    Wan, Zheng
    Shi, Man
    Gong, Yanqing
    Lucci, Massimo
    Li, Jinjin
    Zhou, Jiahai
    Yang, Xiao-Liang
    Lelli, Moreno
    He, Xiao
    Mao, Jiafei
    MOLECULES, 2024, 29 (02):
  • [30] A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
    Jackson, A. G. A.
    Else, L. J.
    Mesquita, P. M. M.
    Egan, D.
    Back, D. J.
    Karolia, Z.
    Ringner-Nackter, L.
    Higgs, C. J.
    Herold, B. C.
    Gazzard, B. G.
    Boffito, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (03) : 314 - 323